Adma Biologics (ADMA) Cost of Revenue (2011 - 2026)

Adma Biologics (ADMA) has 13 years of Cost of Revenue data on file, last reported at -$162.2 million in Q4 2025.

• Quarterly Cost of Revenue fell 179.55% year-over-year to -$162.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$47.6 million (down 117.88% YoY) and the FY2025 annual result came in at $4.8 million, down 97.66% from the prior year.
• Cost of Revenue eased to -$162.2 million in Q4 2025, from $58.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $203.9 million in Q4 2024 to a low of -$162.2 million in Q4 2025.
• A 5-year average of $22.1 million and a median of $3.0 million in 2021 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2021 — Cost of Revenue tumbled 333.42% — and 2024, when it jumped 12786.51%.
• Tracing ADMA's Cost of Revenue over 5 years: stood at -$44.6 million in 2021, then soared by 180.26% to $35.8 million in 2022, then surged by 362.76% to $165.7 million in 2023, then grew by 23.08% to $203.9 million in 2024, then sank by 179.55% to -$162.2 million in 2025.
• The last three Cost of Revenue figures came in at -$162.2 million (Q4 2025), $58.6 million (Q3 2025), and $54.8 million (Q2 2025), per Business Quant data.